A new multimodal tool combines a large language model with powerful graph-based AI models to efficiently find new, synthesizable molecules with desired properties, based on a user’s queries in plain language.

A research team from Helmholtz Munich and the Technical University of Munich has developed an advanced delivery system that transports gene-editing tools based on the CRISPR/Cas9 gene-editing system into living cells with significantly greater efficiency than before. Their technology, ENVLPE, uses engineered non-infectious virus-like particles to precisely correct defective genes – demonstrated successfully in living mouse models that are blind due to a mutation. This system also holds promise for advancing cancer therapy by enabling precise genetic manipulation of engineered immune cells making them more universally compatible and thus more accessible for a larger group of cancer patients.

Investigators from Mass General Brigham and Beth Israel Deaconess Medical Center have developed STITCHR, a new gene editing tool that can insert therapeutic genes into specific locations without causing unwanted mutations. The system can be formulated completely as RNA, dramatically simplifying delivery logistics compared to traditional systems that use both RNA and DNA. By inserting an entire gene, the tool offers a one-and-done approach that overcomes hurdles from CRISPR gene editing technology—which is programmed to correct individual mutations—offering a promising step forward for gene therapy. Results are published in Nature.